[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333963-105":59,"doc-detail-333963-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","immunogenic-cell-death-inducers-and-pd-1-blockade-as-neoadjuvant-therapy-for-rectal-cancer","Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer","","Immuno-oncological cancer management is shifting toward neoadjuvant treatments, where complete responses in locally advanced rectal cancer can avoid surgery. Recent clinical evidence supports safe perioperative chemoimmunotherapy, combining oxaliplatin-based chemotherapy with PD-1/PD-L1 blockade before surgery with curative intent. This work contextualizes immunotherapy-based total neoadjuvant therapy, highlights immunogenic cell death inducers within the regimen, and explains how danger-associated signals can sensitize tumors to PD-1 inhibition.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunogenic-cell-death-inducers-and-pd-1-blockade-as-neoadjuvant-therapy-for-rectal-cancer/333963/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunogenic-cell-death-inducers-and-pd-1-blockade-as-neoadjuvant-therapy-for-rectal-cancer/333963.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How do components of the iTNT regimen contribute to immunogenic sensitization to PD-1 inhibition?","Question",{"text":112,"@type":113},"Oxaliplatin, fluorouracil, and X-ray irradiation can induce immunogenic cell death, triggering danger-associated molecular patterns and adaptive immune responses that enhance the effect of PD-1 blockade.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},333963,1790325605,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":131,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":67,"update_tm":135,"read_time":39,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","ONCOIMMUNOLOGY  \n2024, VOL. 13, NO. 1, 2416558 [https://doi.org/10.1080/2162402X.2024.2416558](https://doi.org/10.1080/2162402X.2024.2416558)  \nImmunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer  \nYan Wanga,b,c,d*, Liwei Zhaoe,f*, Zhen Zhanga,b,c,d, and Peng Liu e,f  \naDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; bDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; cShanghai Clinical Research Center for Radiation Oncology, Shanghai, China; dShanghai Key Laboratory of Radiation Oncology, Shanghai, China; eCentre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Paris, France; fMetabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France  \nABSTRACT  \nImmuno-oncological cancer management is shifting to neoadjuvant treatments. In patients with gastrointestinal cancers, particularly locally advanced rectal cancer, neoadjuvant chemoimmunotherapy often induce complete responses, hence avoiding surgical intervention. Recent clinical trials indicate that combinations of oxaliplatin-based chemotherapy and PD-1/PD-L1-targeting immunotherapy can be safely administered before surgery with curative intent.  \nARTICLE HISTORY  \nReceived 24 September 2024 Revised 10 October 2024 Accepted 10 October 2024  \nKEYWORDS  \nCancer immunotherapy; Immunogenic cell death; Fc receptor; Immune checkpoint inhibitor; Total neoadjuvant therapy  \nTotal neoadjuvant therapy (TNT) is an evolving approach for the treatment of certain malignancies, including locally advanced rectal cancer (LARC), where neoadjuvant chemotherapy and/or radiation therapy is administered before surgery rather than in an interspersed manner where some treatment is given before and some after surgery (Figure 1a–d). Thus, TNT aims at maximizing the benefits ofneoadjuvant therapy by delivering a comprehensive course of treatment prior to surgical resection of the tumor. The integration of PD-1-targeted immune checkpoint blockade into TNT offers the chance to additionally (re-)activate anticancer immunity, hence increasing the likelihood of complete tumor eradication and reducing the risk of metastasis.  \nRecently, Zhang Z et al.1 presented results from a phase II trial of immunotherapy-based TNT (iTNT) for proficient mismatch repair or microsatellite stable (pMMR/MSS) LARC (Clinical Trial Information, NCT04518280-TORCH). In this study, the complete response rates (CR rate, 54.2% ~ 56.5%) were significantly higher as compared with conventional neoadjuvant chemoradiotherapy, or some studies involving similar agents but not TNT (CR rate 39.8% ~ 44.8%), indicating that iTNT was profoundly more efficient even in tumors with limited immune infiltrate prior to treatment. Indeed, pMMR/MSS LARC is immunologically relatively cold and refractory to neoadjuvant PD-1 blockade (without chemotherapy) compared to deficient mismatch repair or microsatellite stable (dMMR/MSI) LARC. Of note, three components in the iTNT regimen, namely oxaliplatin, fluorouracil (the active metabolite of capecitabine), as well as X-ray irradiation, have been well described for their ability to induce immunogenic cell  \ndeath (ICD) that can sensitize tumors to PD-1 blockade, the final component ofthe iTNT regimen.2–4  \nICD is a specific form of cellular demise that elicits adaptive immune responses against dead-cell antigens and establishes durable immunological memory.3,4 In addition to their known direct anti-proliferative effects on cancer cells, bona fide ICD inducers are endowed with the ability to remodel immunosurveillance, as demonstrated by their capability to induce anticancer vaccination effects in immunocompetent mouse models.3 ICD-inducing chemotherapies trigger a pre-mortem stress response in malignant cells, such as endoplasmic reticulum (ER) stress and autoph","cbCaiaIG5XEwu8Lr","https://ap.wps.com/l/cbCaiaIG5XEwu8Lr","pdf",730585,"English","# Abstract\n## Neoadjuvant immunotherapy and total neoadjuvant therapy\n## iTNT efficacy in pMMR/MSS locally advanced rectal cancer\n## Immunogenic cell death mechanisms and immune activation\n## ICD-induced sensitization to PD-1 blockade","[{\"question\":\"How do components of the iTNT regimen contribute to immunogenic sensitization to PD-1 inhibition?\",\"answer\":\"Oxaliplatin, fluorouracil, and X-ray irradiation can induce immunogenic cell death, triggering danger-associated molecular patterns and adaptive immune responses that enhance the effect of PD-1 blockade.\"}]","Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer | PDF",1790004790]